One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
-
Patent number: 10143792Abstract: Medicament delivery devices for administration of opioid antagonists are described herein. In some embodiments, an apparatus includes a housing, a medicament container disposed within the housing and an energy storage member disposed within the housing. The medicament container is filled with a naloxone composition that includes naloxone or salts thereof, a tonicity-adjusting agent, and a pH adjusting agent, whereby the osmolality of the naloxone composition ranges from about 250-350 mOsm and the pH ranges from about 3-5. The energy storage member is configured to produce a force to deliver the naloxone composition.Type: GrantFiled: October 21, 2016Date of Patent: December 4, 2018Assignee: kaleo, Inc.Inventors: Eric S. Edwards, Evan T. Edwards, Mark J. Licata, Frank E. Blondino
-
Patent number: 10131672Abstract: A therapeutic or prophylactic agent for biliary tract diseases includes as an effective component a specific compound having a morphinan skeleton represented by Compound 1, or a pharmaceutically acceptable acid addition salt thereof:Type: GrantFiled: January 28, 2011Date of Patent: November 20, 2018Assignee: Toray Industries, Inc.Inventors: Ryosuke Kobayashi, Kaoru Nakao
-
Patent number: 10130657Abstract: A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxidation therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.Type: GrantFiled: February 14, 2016Date of Patent: November 20, 2018Inventor: John C. Hughes
-
Patent number: 10064956Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: November 14, 2017Date of Patent: September 4, 2018Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Patent number: 10045977Abstract: The present invention relates to new medical uses of morphinans such as nalmefene and naltrexone and their related derivatives, pharmaceutical formulations thereof, and use thereof for prevention and treatment of NASH, NAFLD, and/or ASH.Type: GrantFiled: April 20, 2017Date of Patent: August 14, 2018Assignee: TAIWANJ PHARMACEUTICALS CO., LTD.Inventors: Edwin S C Wu, Peter J. S. Chiu, May Mei-chi Hsu
-
Patent number: 10028967Abstract: Suggested is a medicament which is particularly useful for preventing, curing or abating of cough and inflammations of the respiratory system, comprising or consisting of active pharmaceutical ingredients and 1,3-propandiol.Type: GrantFiled: June 27, 2015Date of Patent: July 24, 2018Assignee: Symrise AGInventors: Donna Rosa, Jakob Ley, Gerhard Krammer, Deborah Kennison
-
Patent number: 10017736Abstract: A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.Type: GrantFiled: July 11, 2013Date of Patent: July 10, 2018Assignee: Pain Therapeutics, Inc.Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
-
Patent number: 10016502Abstract: An object of the present invention is to provide a patch preparation having an excellent skin permeability of medicament using an acid additional salt of basic medicament. Provided is a patch preparation comprising a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a basic medicament, a fatty acid-based ionic liquid, and potassium salts and/or potassium ions. Said potassium salts and/or potassium ions are generated as a result of reaction of an acid addition salt of the basic medicament with a compound capable of generating potassium ion in the adhesive layer.Type: GrantFiled: September 28, 2016Date of Patent: July 10, 2018Assignee: MEDRx Co., LTDInventors: Hidetoshi Hamamoto, Takahiro Tanimoto
-
Patent number: 9987269Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxymorphone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.Type: GrantFiled: December 1, 2015Date of Patent: June 5, 2018Assignee: 3ST Research LLCInventor: John K. Thottathil
-
Patent number: 9987268Abstract: The present invention relates to methods of treating metabolic syndrome Type 2 diabetes mellitus atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective ?-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.Type: GrantFiled: September 8, 2014Date of Patent: June 5, 2018Assignee: NEURENDO PHARMA, LLCInventor: Anton H. Clemens
-
Patent number: 9974858Abstract: The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promoter. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.Type: GrantFiled: September 28, 2016Date of Patent: May 22, 2018Assignee: MEDRx CO., LTDInventors: Yasushi Miwa, Hidetoshi Hamamoto, Naoya Akazawa
-
Patent number: 9949930Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.Type: GrantFiled: July 17, 2014Date of Patent: April 24, 2018Assignee: Purdue Pharma L.P.Inventors: Christopher Breder, Curtis Wright, Benjamin Oshlack
-
Patent number: 9938285Abstract: Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.Type: GrantFiled: January 15, 2015Date of Patent: April 10, 2018Assignee: RHODES TECHNOLOGIESInventors: Joshua Robert Giguere, Keith Edward McCarthy, Marcel Schleusner
-
Patent number: 9932348Abstract: Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.Type: GrantFiled: January 15, 2015Date of Patent: April 3, 2018Assignee: RHODES TECHNOLOGIESInventors: Joshua Robert Giguere, Keith Edward McCarthy, Marcel Schleusner
-
Patent number: 9931337Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: December 5, 2014Date of Patent: April 3, 2018Assignee: Purdue Pharma L.P.Inventors: Michelle Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9926328Abstract: Crystalline, anhydrous hydrochloride salts of 4,5?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt as a medicament and for the treatment and/or prevention of pain.Type: GrantFiled: September 12, 2016Date of Patent: March 27, 2018Assignee: ENDO PHARMACEUTICALS INC.Inventors: Andreas Fischer, Dagmar Peters-Groth, Dagmar Lischke
-
Patent number: 9925182Abstract: The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.Type: GrantFiled: September 1, 2016Date of Patent: March 27, 2018Assignee: Nektar TherapeuticsInventors: Timothy A. Riley, Juergen W. Pfeiffer, Hema Gursahani
-
Patent number: 9918978Abstract: The invention relates to a composition comprising buprenorphine and ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: March 10, 2016Date of Patent: March 20, 2018Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel Deaver, Elliot Ehrich
-
Patent number: 9913837Abstract: The invention relates to a composition comprising buprenorphine and a ? opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ? ( BUP ) / EC 50 ] [ C max ? ( ANTAGONIST ) / IC 50 ] .Type: GrantFiled: September 12, 2016Date of Patent: March 13, 2018Assignee: Alkermes Pharma Ireland LimitedInventors: Daniel Deaver, Elliot Ehrich
-
Patent number: 9908891Abstract: The present invention provides processes for preparing morphinan-6-one compounds, in particular oxymorphone and salts thereof, having improved impurity profiles.Type: GrantFiled: February 5, 2014Date of Patent: March 6, 2018Assignee: Johnson Matthey Public Limited CompanyInventors: Nicolas Archer, Timothy Davies, Amy Price, Maureen Young
-
Patent number: 9884059Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: March 26, 2015Date of Patent: February 6, 2018Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9877925Abstract: A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.Type: GrantFiled: March 11, 2015Date of Patent: January 30, 2018Assignee: ETHYPHARMInventors: Catherine Herry, Laury Trichard
-
Patent number: 9872856Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: February 3, 2015Date of Patent: January 23, 2018Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9867783Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: March 4, 2015Date of Patent: January 16, 2018Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Patent number: 9867817Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: March 26, 2015Date of Patent: January 16, 2018Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9855262Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: March 26, 2015Date of Patent: January 2, 2018Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9849124Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: October 16, 2015Date of Patent: December 26, 2017Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9849185Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-?-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: December 30, 2016Date of Patent: December 26, 2017Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Patent number: 9820982Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphine which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.Type: GrantFiled: July 3, 2002Date of Patent: November 21, 2017Assignee: ENDO PHARMACEUTICALS INC.Inventors: Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
-
Patent number: 9814710Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.Type: GrantFiled: November 13, 2014Date of Patent: November 14, 2017Assignee: Euro-Celtique S.A.Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
-
Patent number: 9815844Abstract: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.Type: GrantFiled: March 10, 2014Date of Patent: November 14, 2017Assignee: KemPharm, Inc.Inventors: Brian W. Heinrich, Da-Ming Gou, Mahmoud Mirmehrabi, Bernhard Paul, Daniel James Coughlin
-
Patent number: 9808433Abstract: The present invention relates to veterinary pharmaceutical compositions for the treatment of pain and inflammation, containing a combination of Tramadol and Firocoxib, for oral administration.Type: GrantFiled: February 17, 2011Date of Patent: November 7, 2017Assignee: FORMEVET S.R.L.Inventors: Andrea Formenti, Filippo Formenti
-
Patent number: 9808431Abstract: Disclosed is an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.Type: GrantFiled: January 9, 2017Date of Patent: November 7, 2017Assignee: Sovereign Pharmaceuticals, LLCInventor: Paul Hafey
-
Patent number: 9801875Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.Type: GrantFiled: August 28, 2015Date of Patent: October 31, 2017Assignee: Orexigen Therapeutics, Inc.Inventors: Preston Klassen, Kristin Taylor
-
Patent number: 9789104Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: GrantFiled: July 1, 2015Date of Patent: October 17, 2017Assignee: LOCL PHARMA, INC.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 9776971Abstract: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.Type: GrantFiled: September 9, 2011Date of Patent: October 3, 2017Assignee: TaiwanJ Pharmaceuticals Co., Ltd.Inventors: Edwin S. C. Wu, Mao-Hsiung Yen, Chin-Tsai Fan
-
Patent number: 9777011Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: March 2, 2016Date of Patent: October 3, 2017Assignees: PURDUE PHARMA L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., RHODES TECHNOLOGIESInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 9757372Abstract: The present invention relates to new medical uses of morphinans such as naltrexone, nalmefene and their related derivatives. The present invention relates to Toll-like receptor 4 (TLR4) antagonist compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of autoimmune liver diseases including but not limited to autoimmune hepatitis.Type: GrantFiled: March 23, 2016Date of Patent: September 12, 2017Assignee: TaiwanJ Pharmaceuticals Co., Ltd.Inventors: Peter J S Chiu, Mei-chi Hsu, Ying-Chu Shih, Edwin S C Wu
-
Patent number: 9737490Abstract: The invention relates to a pharmaceutical dosage form comprising (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further segment (S2), which contains a second pharmacologically active ingredient (A2) and provides immediate release thereof, wherein the at least one formed segment (S1) exhibits a higher breaking strength than the at least one further segment (S2) and the at least one formed segment (S1) exhibits a breaking strength of more than 500 N.Type: GrantFiled: May 27, 2014Date of Patent: August 22, 2017Assignee: GRÜNENTHAL GMBHInventors: Lutz Barnscheid, Anja Geiβler, Klaus Wening, Stefanie Strauch, Jana Pätz, Sebastian Schwier
-
Patent number: 9724343Abstract: The present invention provides a compound of formua I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.Type: GrantFiled: September 26, 2016Date of Patent: August 8, 2017Assignee: Wyeth, LLCInventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
-
Patent number: 9713611Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.Type: GrantFiled: June 3, 2016Date of Patent: July 25, 2017Assignee: Recro Gainesville, LLCInventors: Gurvinder Singh Rekhi, Richard Sidwell
-
Patent number: 9707179Abstract: A pharmaceutical composition for controlled release of an active substance is provided. The active substance is released into an aqueous medium by erosion of at least one surface of the composition. The composition comprises i) a matrix comprising a) polymer or a mixture of polymers, b) an active substance and, optionally, c) one or more pharmaceutically acceptable excipients, and ii) a coating.Type: GrantFiled: July 15, 2014Date of Patent: July 18, 2017Assignee: EGALET LTD.Inventors: Gina Fischer, Daniel Bar-Shalom, Lillian Slot, Christine Andersen
-
Patent number: 9700520Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, comprising at least one pharmaceutical active ingredient, which is an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further contains 110 to 250% by weight, calculated on dry weight of the polymer mixture, of a non-porous inert lubricant and the coating layer is present in an amount of at least 60% by weight calculated on the weight of core.Type: GrantFiled: September 25, 2007Date of Patent: July 11, 2017Assignee: Evonik Roehm GmbHInventors: Hans-Ulrich Petereit, Hema Ravishankar, Ashwini Samel
-
Patent number: 9700553Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.Type: GrantFiled: September 12, 2016Date of Patent: July 11, 2017Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9700508Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.Type: GrantFiled: May 10, 2011Date of Patent: July 11, 2017Assignee: Euro-Celtique S.A.Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
-
Patent number: 9669096Abstract: Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.Type: GrantFiled: September 27, 2013Date of Patent: June 6, 2017Assignee: Progenics Pharmaceuticals, Inc.Inventors: Suketu P. Sanghvi, Thomas A. Boyd
-
Patent number: 9662326Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.Type: GrantFiled: February 26, 2015Date of Patent: May 30, 2017Assignee: Purdue Pharma L.P.Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
-
Patent number: 9662399Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.Type: GrantFiled: March 27, 2015Date of Patent: May 30, 2017Assignee: Purdue Pharma L.P.Inventors: Debora Guido, Haiyong Hugh Huang
-
Patent number: 9662390Abstract: The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: GrantFiled: March 7, 2006Date of Patent: May 30, 2017Assignee: THE UNIVERSITY OF CHICAGOInventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G. N. Garcia
-
Patent number: 9655855Abstract: The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.Type: GrantFiled: September 17, 2014Date of Patent: May 23, 2017Assignee: Purdue Pharma L.P.Inventors: Bianca Brögmann, Silke Mühlau, Christof Spitzley